Parkinson's Disease Nervous System Diseases Parkinson disease
Conditions
Interventions
Current interventions as of 24/05/2022:
This is now a parallel group design which means that after participants have been screened for eligibility, they will be assessed, and randomly allocated to o
Sponsors
Northumbria University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinical diagnosis of Parkinson’s by a movement disorder specialist according to UK brain bank criteria (Hoehn and Yahr stage I-III) 2. Aged >50 years 3. Able to walk and stand without support or assistance from another person 4. Have adequate hearing/vision capabilities to allow participation in all aspects of the study (if participant wears prescription glasses, they must be comfortable to remove these for short periods of up to 5 min at a time in order to take part in activities whilst wearing strobe glasses) 5. Stable medication for the previous 1 month and anticipated over a period of 6 months.
Exclusion criteria
Exclusion criteria: 1. History of epilepsy, seizures, migraines, severe motion sickness, or sensitivity to light 2. Psychiatric co-morbidity (such as major depressive disorder as determined by a geriatric depression scale [GDS-15] score <10) 3. Clinical diagnosis of dementia or other severe cognitive impairment 4. History of stroke, traumatic brain injury, MS, or neurological disorders other than Parkinson’s disease 5. Acute lower back or lower extremity pain, peripheral neuropathy, or rheumatic and orthopaedic diseases 6. Unstable medical conditions including cardio-vascular instability in the past 6 months 7. Unable to comply with the testing protocol 8. Currently participating in another interfering research project or undergoing any interfering therapy 9. Have not had the opportunity to receive a COVID-19 vaccine (individuals may still be included in the study if they have been offered the vaccine but have declined due to personal circumstances) 10. If experiencing COVID-19 symptoms individuals will be managed as per the latest government guidelines
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 24/05/2022: Feasibilty measures Visual attention measured using the Visual Trail Making Test (TMT) Parts A and B at baseline and after the intervention period. _____ Previous primary outcome measure: Visual attention measured using the Visual Trail Making Test (TMT) Parts A and B at baseline, 4, and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Mood measured using the Geriatric depression scale (GDS-15) at baseline 2. General cognition measured using the following: 2.1. Montreal cognitive assessment (MoCA) at baseline 2.2. The Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15) at baseline, 4, and 12 weeks 2.3. Attention Computer Battery at baseline, 4, and 12 weeks 3. Visuospatial ability measured using Benton’s Judgement of Line Orientation Test and the Clock copying task (Royall’s CLOX 1 + 2) at baseline, 4, and 12 weeks 4. Visual acuity measured using LogMAR at baseline, 4, and 12 weeks 5. Contrast sensitivity measured using the Mars Letter Contrast Sensitivity Test at baseline, 4, and 12 weeks 6. Visual and sensorimotor skills measured using Senaptec Sensory Station at baseline, 4, and 12 weeks 7. Parkinson's disease status measured using the Hoehn & Yahr (H & Y) scale at baseline 8. Motor symptoms measured using the Unified Parkinson's Disease Rating Scale (UPDRS-III) at baseline, 4, and 12 weeks 9. Freezing of Gait measured using the new Freezing of Gait questionnaire (FOGQ) at baseline, 4, and 12 weeks 10. Falls measured using the Falls efficacy scale- International (FES-I) at baseline, 4, and 12 weeks 11. Quality of Life measured using Parkinson’s Disease Questionnaire- 39 (PDQ-39) at baseline, 4, and 12 weeks 12. Balance measured using Mini Best Test at baseline, 4, and 12 weeks 13. Gait measured using Timed up and Go and the 10 m walk test at baseline, 4, and 12 weeks 14. Fatigue measured using the Fatigue Severity Scale at baseline, 4, and 12 weeks 15. Participation (effort/motivation) measured using Pittsburgh Rehabilitation Participation Scale at baseline, 4, and 12 weeks 16. Usability of visual training technology measured using Systems Usability Scale at either 4 weeks or 12 weeks 17. Participant experience measured using Semi-structured Interviews at 12 weeks | — |
Countries
England, United Kingdom
Outcome results
None listed